AI can help protein engineers optimize the transcription enzymes used to make mRNA-based vaccines and therapeutics, say the authors of a new study.

UVA Health scientists are reporting promising success as they pioneer a new way to create vaccines far more quickly, nimbly ...

Experts worry Robert F. Kennedy Jr.’s Health Department will use an internal AI tool to analyze vaccine injury claims in a ...

The most recent analyst rating on (MRNA) stock is a Sell with a $27.00 price target. To see the full list of analyst forecasts on Moderna stock, see the MRNA Stock Forecast page. According to Spark, ...

Moderna just got an unusually cold shoulder from the FDA over its latest vaccine push, the New York Times reports. The company says regulators have refused to even review its application for an ...

In this week’s edition of InnovationRx, we look at the healthcare giants on Forbes new Greatest Innovators list, why Garner ...

CAMBRIDGE, Mass., August 28, 2025 – Raina Biosciences Inc., (“Raina”), an mRNA technology and therapeutics company, today announced the publication of data from its generative AI platform in Science.

Moderna faces a setback as U.S. regulators refuse to review its experimental flu vaccine, reflecting changes in vaccination policies. This decision impacts Moderna's mRNA strategy, raising concerns ...

Moderna faces a setback as shares drop 9% due to the FDA's refusal to review its influenza vaccine application. This decision ...

Houston Methodist Research Institute is collaborating with the Coalition for Epidemic Preparedness Innovations (CEPI) and leading scientific institutions in the Republic of Korea to develop what could ...

We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy. On January 28, Barclays assumed coverage ...